Merifin Capital

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy. The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names in Spain, Brazil, Mexico and Indonesia (TechCrunch).

DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy. The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names in Spain, Brazil, Mexico and Indonesia (TechCrunch).

Launched in 2013 in France, Flayr is a unique place for shopping discoveries, allowing people to discover outsourced and crowdsourced edgy little brands and take benefit of great deals on big brands. Flayr is very user-centric, designed only to fulfill their users' every needs. Flayr is developped in Paris, Caen (yes, Caen, Normandy-based city somewhere in France is the new Palo Alto) & USA by Olivier, Nicolas, Philippe, Jerome, Pierre, Delphine, Clémence, Arnaud, Valentin, Jérôme, Antoine, Antoine, Julie, Nabil, Tiphaine, Guillaume, Julien, Isaline, Romain, David, Cassio, and Arthur. France finally found its fourth F: "Fashion, Fragrance, Fromage and Flayr"!

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Plastic Logic Germany leads the way in developing, manufacturing and commercializing flexible displays. The company has successfully industrialized the manufacturing process in its facility, the world’s first commercial, volume, organic electronics factory. Using a stable and proven licensed technology transistor platform, the company manufactures a range of high-quality, flexible plastic displays. These shatterproof, daylight-readable displays are ultra-thin, ultra-lightweight and very low-power, offering huge advantages over conventional screens as they are extremely robust with proven lifetimes. Plastic Logic Germany also runs an open pilot line for flexible electronics. Third party companies are invited to benefit from the company’s years of experience in the industrialization and manufacture of flexible electronics. Plastic Logic Germany’s customers include OEMs and electronics manufacturers for signage and logistics, mobile electronic devices, smart-cards, wearables and more. For more information, please visit www.plasticlogic.com.

Metara manufactures chemical metrology tools for semiconductor industry that are used in monitoring and controlling chemical processes. Its products include sentry trace contamination metrology system, which monitors benign chemistries for trace contaminants; and sentry chemical composition metrology system, which monitors copper electroplating and cobalt bath chemistries. The company also offers sentry harsh chemistry metrology system, an analysis solution for harsh chemistries used in semiconductor manufacturing processes; and inline mass spectrometer, a chemical metrology solution that determines chemical composition and potential yield-or process-limiting contaminants. Metara Inc. was founded in 2000 and is headquartered in Sunnyvale, California.

DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.

Optiva is mission-critical, cloud-native monetization and revenue management software on the private and public cloud. It is recognized by the industry for its disruptive and innovative approach beyond the cloud. Operators that leverage solutions gain the freedom to experiment with new capabilities with speed and agility. The result is the rapid introduction of new customer offerings services and commercial models to accelerate their business velocity.